| 1 | A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B | 3.6 | 13 | Citations (PDF) |
| 2 | AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment | 3.6 | 9 | Citations (PDF) |
| 3 | Can we use old NAFLD data under the new MASLD definition? | 3.6 | 287 | Citations (PDF) |
| 4 | A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis | 10.6 | 68 | Citations (PDF) |
| 5 | Risk of liver-related events in metabolic dysfunction–associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria | 10.6 | 14 | Citations (PDF) |
| 6 | Iron status and non-alcoholic fatty liver disease: A Mendelian randomization study | 2.9 | 4 | Citations (PDF) |
| 7 | Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B | 3.6 | 35 | Citations (PDF) |
| 8 | Unmet need in screening for hepatitis D virus: Time to take action | 3.6 | 3 | Citations (PDF) |
| 9 | Machine‐learning model comprising five clinical indices and liver stiffness measurement can accurately identify <scp>MASLD</scp>‐related liver fibrosis | 4.1 | 19 | Citations (PDF) |
| 10 | Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease | 3.9 | 88 | Citations (PDF) |
| 11 | Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease <scp>–</scp> The Gut and Obesity in Asia (GO‐ASIA) Study | 3.9 | 17 | Citations (PDF) |
| 12 | Performance of continuous controlled attenuation parameter and liver stiffness measurement by the novel <scp>SmartExam</scp> in metabolic dysfunction‐associated steatotic liver disease | 4.1 | 9 | Citations (PDF) |
| 13 | Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort | 4.1 | 7 | Citations (PDF) |
| 14 | <scp>CAMP‐B</scp> score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after <scp>HBsAg</scp> seroclearance | 3.9 | 8 | Citations (PDF) |
| 15 | The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease | 4.8 | 22 | Citations (PDF) |
| 16 | Diagnostic accuracy of non‐invasive tests to screen for at‐risk <scp>MASH</scp>—An individual participant data meta‐analysis | 4.1 | 15 | Citations (PDF) |
| 17 | Title is missing! 2024 | | 0 | Citations (PDF) |
| 18 | A mini-review on prebiotic inulin to prevent and treat non-alcoholic fatty liver disease | 5.4 | 6 | Citations (PDF) |
| 19 | A pilot integrated model nurse clinic increases the uptake of antiviral treatment for the prevention of mother‐to‐child transmission of <scp>HBV</scp> | 4.1 | 3 | Citations (PDF) |
| 20 | Diagnosis and non‐invasive assessment of <scp>MASLD</scp> in type 2 diabetes and obesity | 3.9 | 14 | Citations (PDF) |
| 21 | <scp>AI</scp>‐powered prediction of <scp>HCC</scp> recurrence after surgical resection: Personalised intervention opportunities using patient‐specific risk factors | 4.1 | 9 | Citations (PDF) |
| 22 | Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease | 21.2 | 55 | Citations (PDF) |
| 23 | Dynamic Changes in ELF Score Predict Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Antiviral Treatment | 2.1 | 0 | Citations (PDF) |
| 24 | Viral Load–Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B | 10.4 | 18 | Citations (PDF) |
| 25 | Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials | 6.2 | 21 | Citations (PDF) |
| 26 | Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver disease | 10.6 | 42 | Citations (PDF) |
| 27 | Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice | 4.8 | 29 | Citations (PDF) |
| 28 | Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis | 21.2 | 81 | Citations (PDF) |
| 29 | Comparison of Single Molecule, Real-Time Sequencing and Nanopore Sequencing for Analysis of the Size, End-Motif, and Tissue-of-Origin of Long Cell-Free DNA in Plasma | 1.1 | 54 | Citations (PDF) |
| 30 | Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores | 3.6 | 164 | Citations (PDF) |
| 31 | Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease | 3.9 | 30 | Citations (PDF) |
| 32 | Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study | 3.9 | 3 | Citations (PDF) |
| 33 | The utility of non‐invasive tests to assess advanced fibrosis in Asian subjects with chronic hepatitis B and concomitant hepatic steatosis | 4.1 | 8 | Citations (PDF) |
| 34 | Implications of comorbidities in nonalcoholic fatty liver disease | 8.7 | 2 | Citations (PDF) |
| 35 | Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes | 10.6 | 41 | Citations (PDF) |
| 36 | Changing epidemiology, global trends and implications for outcomes of NAFLD | 3.6 | 543 | Citations (PDF) |
| 37 | Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis | 10.6 | 25 | Citations (PDF) |
| 38 | Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease | 4.8 | 3 | Citations (PDF) |
| 39 | A global research priority agenda to advance public health responses to fatty liver disease | 3.6 | 103 | Citations (PDF) |
| 40 | Risk factors for sessile serrated lesions among Chinese patients undergoing colonoscopy | 2.7 | 5 | Citations (PDF) |
| 41 | Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages | 2.7 | 9 | Citations (PDF) |
| 42 | Incidence of hepatocellular carcinoma and mortality in chronic viral hepatitis in an Asian population with and without HIV infection | 3.9 | 7 | Citations (PDF) |
| 43 | Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial | 21.2 | 38 | Citations (PDF) |
| 44 | Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis | 3.9 | 19 | Citations (PDF) |
| 45 | <scp>MAFLD</scp> fibrosis score: Using routine measures to identify advanced fibrosis in metabolic‐associated fatty liver disease | 3.9 | 19 | Citations (PDF) |
| 46 | Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD) | 4.7 | 12 | Citations (PDF) |
| 47 | Liver stiffness measurement predicts short-term and long-term outcomes in patients with hepatocellular carcinoma after curative liver resection | 2.4 | 11 | Citations (PDF) |
| 48 | Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial | 21.2 | 196 | Citations (PDF) |
| 49 | Treatment Candidacy for Pharmacologic Therapies for NASH | 6.2 | 35 | Citations (PDF) |
| 50 | Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis | 21.2 | 401 | Citations (PDF) |
| 51 | A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease | 6.2 | 98 | Citations (PDF) |
| 52 | Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma | 21.2 | 108 | Citations (PDF) |
| 53 | Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases | 10.6 | 241 | Citations (PDF) |
| 54 | Fatty Pancreas Is Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study | 6.2 | 57 | Citations (PDF) |
| 55 | Asian perspective on NAFLD-associated HCC | 3.6 | 127 | Citations (PDF) |
| 56 | Association of genetic variations with NAFLD in lean individuals | 4.1 | 64 | Citations (PDF) |
| 57 | Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study | 9.5 | 47 | Citations (PDF) |
| 58 | Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis | 10.6 | 125 | Citations (PDF) |
| 59 | U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases | 8.7 | 30 | Citations (PDF) |
| 60 | Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry | 6.2 | 88 | Citations (PDF) |
| 61 | Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD | 9.5 | 30 | Citations (PDF) |
| 62 | Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis | 4.8 | 41 | Citations (PDF) |
| 63 | Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis | 3.9 | 37 | Citations (PDF) |
| 64 | Non-invasive tests of non-alcoholic fatty liver disease | 4.7 | 44 | Citations (PDF) |
| 65 | Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease | 10.6 | 77 | Citations (PDF) |
| 66 | Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study | 0.5 | 1 | Citations (PDF) |
| 67 | Letter: systematic review with meta‐analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B | 3.9 | 1 | Citations (PDF) |
| 68 | A cholestatic pattern predicts major liver‐related outcomes in patients with non‐alcoholic fatty liver disease | 4.1 | 11 | Citations (PDF) |
| 69 | Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study | 2.0 | 48 | Citations (PDF) |
| 70 | Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease | 10.6 | 47 | Citations (PDF) |
| 71 | The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? | 3.6 | 219 | Citations (PDF) |
| 72 | An international survey on patterns of practice in NAFLD and expectations for therapies—The POP‐NEXT project | 10.6 | 14 | Citations (PDF) |
| 73 | Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems | 2.7 | 13 | Citations (PDF) |
| 74 | Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population | 6.2 | 231 | Citations (PDF) |
| 75 | Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease | 4.8 | 10 | Citations (PDF) |
| 76 | Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018 | 4.7 | 27 | Citations (PDF) |
| 77 | Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate | 3.8 | 10 | Citations (PDF) |
| 78 | Single-Molecule Sequencing Enables Long Cell-Free DNA Detection and Direct Methylation Analysis for Cancer Patients | 1.1 | 63 | Citations (PDF) |
| 79 | Characterization and correction of the effects of hepatic iron on <i>T</i><sub>1ρ</sub> relaxation in the liver at 3.0T | 2.8 | 7 | Citations (PDF) |
| 80 | Inhomogeneous liver fibrosis distribution revealed by macromolecular proton fraction quantification based on spin-lock MRI | 1.5 | 1 | Citations (PDF) |
| 81 | Current therapies and new developments in NASH | 21.2 | 165 | Citations (PDF) |
| 82 | Universal <scp>HBV</scp> vaccination dramatically reduces the prevalence of <scp>HBV</scp> infection and incidence of hepatocellular carcinoma | 3.9 | 44 | Citations (PDF) |
| 83 | Management of <scp>NAFLD</scp> in primary care settings | 4.1 | 70 | Citations (PDF) |
| 84 | Letter: vaccination for global control of hepatitis B—from prevention to elimination. Authorsʼ reply | 3.9 | 0 | Citations (PDF) |
| 85 | Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B | 6.2 | 25 | Citations (PDF) |
| 86 | Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease | 6.2 | 147 | Citations (PDF) |
| 87 | Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis–Related, Child–Pugh A Cirrhosis | 6.2 | 73 | Citations (PDF) |
| 88 | Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease | 6.2 | 162 | Citations (PDF) |
| 89 | Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19 | 21.2 | 147 | Citations (PDF) |
| 90 | Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH | 10.6 | 247 | Citations (PDF) |
| 91 | Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong—A Territory-Wide Cohort Study | 5.4 | 30 | Citations (PDF) |
| 92 | ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver‐Related Cirrhosis | 10.6 | 35 | Citations (PDF) |
| 93 | Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B | 2.9 | 21 | Citations (PDF) |
| 94 | The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis | 1.0 | 100 | Citations (PDF) |
| 95 | Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection | 0.7 | 50 | Citations (PDF) |
| 96 | Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019 | 0.4 | 19 | Citations (PDF) |
| 97 | Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study | 2.9 | 16 | Citations (PDF) |
| 98 | Clinical Spectrum and Renal Outcome of Cryoglobulinemia in Hong Kong | 1.9 | 0 | Citations (PDF) |
| 99 | Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog | 2.9 | 26 | Citations (PDF) |
| 100 | Artificial intelligence in prediction of non‐alcoholic fatty liver disease and fibrosis | 2.7 | 63 | Citations (PDF) |
| 101 | Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory‐Wide Cohort Study | 4.7 | 13 | Citations (PDF) |
| 102 | COVID-19 and liver disease: mechanistic and clinical perspectives | 48.0 | 345 | Citations (PDF) |
| 103 | Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis | 23.6 | 213 | Citations (PDF) |
| 104 | Simple non‐invasive scoring systems and histological scores in predicting mortality in patients with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis | 2.7 | 7 | Citations (PDF) |
| 105 | A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery | 3.5 | 16 | Citations (PDF) |
| 106 | Reply | 6.2 | 0 | Citations (PDF) |
| 107 | Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact | 8.7 | 8 | Citations (PDF) |
| 108 | SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19 | 0.8 | 12 | Citations (PDF) |
| 109 | Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B | 3.8 | 74 | Citations (PDF) |
| 110 | Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis | 4.7 | 29 | Citations (PDF) |
| 111 | A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH | 10.6 | 169 | Citations (PDF) |
| 112 | Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need | 1.4 | 20 | Citations (PDF) |
| 113 | Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease | 3.9 | 32 | Citations (PDF) |
| 114 | Non-alcoholic fatty liver disease | 52.8 | 2,283 | Citations (PDF) |
| 115 | Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID‐19 | 10.6 | 49 | Citations (PDF) |
| 116 | Defining comprehensive models of care for NAFLD | 48.0 | 119 | Citations (PDF) |
| 117 | Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment | 2.6 | 15 | Citations (PDF) |
| 118 | TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial | 1.0 | 187 | Citations (PDF) |
| 119 | Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B | 8.7 | 16 | Citations (PDF) |
| 120 | Sodium‐glucose co‐transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B | 0.5 | 3 | Citations (PDF) |
| 121 | Hepatobiliary and Pancreatic: A tree in the liver | 2.7 | 1 | Citations (PDF) |
| 122 | Secular trend of treatment uptake in patients with chronic hepatitis B: A territory‐wide study of 135 395 patients from 2000 to 2017 | 2.7 | 18 | Citations (PDF) |
| 123 | Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease | 2.3 | 38 | Citations (PDF) |
| 124 | Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B‐related cirrhosis and renal impairment | 1.7 | 4 | Citations (PDF) |
| 125 | Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease | 1.0 | 493 | Citations (PDF) |
| 126 | Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper | 2.1 | 132 | Citations (PDF) |
| 127 | A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients | 0.7 | 43 | Citations (PDF) |
| 128 | Advancing the global public health agenda for NAFLD: a consensus statement | 48.0 | 608 | Citations (PDF) |
| 129 | Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong | 2.0 | 21 | Citations (PDF) |
| 130 | Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue‐induced hepatitis B surface antigen loss | 3.9 | 30 | Citations (PDF) |
| 131 | An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory‐Wide Study From 2000 to 2017 | 10.6 | 78 | Citations (PDF) |
| 132 | Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China | 1.0 | 179 | Citations (PDF) |
| 133 | Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy | 21.2 | 40 | Citations (PDF) |
| 134 | Reply to Sun et al | 5.4 | 0 | Citations (PDF) |
| 135 | Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease | 2.7 | 27 | Citations (PDF) |
| 136 | Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure | 3.6 | 71 | Citations (PDF) |
| 137 | Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox | 2.6 | 35 | Citations (PDF) |
| 138 | Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design | 1.6 | 120 | Citations (PDF) |
| 139 | Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease | 6.2 | 26 | Citations (PDF) |
| 140 | The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg‐negative chronic hepatitis B | 4.1 | 20 | Citations (PDF) |
| 141 | Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B | 3.6 | 63 | Citations (PDF) |
| 142 | Liver stiffness measurement predicts long‐term survival and complications in non‐alcoholic fatty liver disease | 4.1 | 107 | Citations (PDF) |
| 143 | ALT Levels for Asians With Metabolic Diseases: A Meta‐analysis of 86 Studies With Individual Patient Data Validation | 4.7 | 25 | Citations (PDF) |
| 144 | Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory‐wide cohort study | 2.7 | 23 | Citations (PDF) |
| 145 | Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement | 23.6 | 91 | Citations (PDF) |
| 146 | East Asia expert opinion on treatment initiation for chronic hepatitis B | 3.9 | 65 | Citations (PDF) |
| 147 | Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes | 4.7 | 51 | Citations (PDF) |
| 148 | Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease | 4.1 | 49 | Citations (PDF) |
| 149 | Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC | 4.8 | 31 | Citations (PDF) |
| 150 | Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus | 2.7 | 25 | Citations (PDF) |
| 151 | Epidemiology of nonalcoholic fatty liver disease in non‐obese populations: Meta‐analytic assessment of its prevalence, genetic, metabolic, and histological profiles | 1.8 | 41 | Citations (PDF) |
| 152 | SGLT2 Inhibitors in Liver Patients | 6.2 | 43 | Citations (PDF) |
| 153 | Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: Data from Hong Kong | 3.1 | 44 | Citations (PDF) |
| 154 | Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease | 0.7 | 51 | Citations (PDF) |
| 155 | Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016 | 7.6 | 76 | Citations (PDF) |
| 156 | Modelling NAFLD disease burden in four Asian regions—2019‐2030 | 3.9 | 143 | Citations (PDF) |
| 157 | Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials | 3.6 | 419 | Citations (PDF) |
| 158 | Endoscopic ultrasound‐guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage | 2.7 | 5 | Citations (PDF) |
| 159 | Macromolecular proton fraction mapping based on spin‐lock magnetic resonance imaging | 2.8 | 12 | Citations (PDF) |
| 160 | Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B | 2.7 | 6 | Citations (PDF) |
| 161 | Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial | 10.6 | 303 | Citations (PDF) |
| 162 | MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease | 1.0 | 2,797 | Citations (PDF) |
| 163 | Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study | 10.6 | 331 | Citations (PDF) |
| 164 | Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study | 10.6 | 76 | Citations (PDF) |
| 165 | FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study | 23.6 | 681 | Citations (PDF) |
| 166 | Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis | 1.0 | 895 | Citations (PDF) |
| 167 | High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study | 2.4 | 8 | Citations (PDF) |
| 168 | Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study | 2.4 | 42 | Citations (PDF) |
| 169 | A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement | 3.6 | 3,642 | Citations (PDF) |
| 170 | Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B | 2.1 | 20 | Citations (PDF) |
| 171 | Use of hepatitis B virus core‐related antigen to evaluate natural history of chronic hepatitis B | 2.7 | 9 | Citations (PDF) |
| 172 | Confounding factors of non-invasive tests for nonalcoholic fatty liver disease | 4.5 | 32 | Citations (PDF) |
| 173 | Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice | 1.1 | 16 | Citations (PDF) |
| 174 | Application of transient elastography in nonalcoholic fatty liver disease | 8.7 | 108 | Citations (PDF) |
| 175 | Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative | 4.8 | 12 | Citations (PDF) |
| 176 | Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative | 4.8 | 0 | Citations (PDF) |
| 177 | Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection—Authors' reply | 3.9 | 0 | Citations (PDF) |
| 178 | Repeating measurements by transient elastography in non‐alcoholic fatty liver disease patients with high liver stiffness | 2.7 | 35 | Citations (PDF) |
| 179 | Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis | 6.2 | 90 | Citations (PDF) |
| 180 | Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials | 10.6 | 247 | Citations (PDF) |
| 181 | THU-237-Increasing prevalence of indications to choose bone/renal-friendly antiviral drug: A territory-wide study of 135,414 patients from 2000 to 2017 | 3.6 | 0 | Citations (PDF) |
| 182 | Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis | 3.9 | 73 | Citations (PDF) |
| 183 | Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis | 1.9 | 37 | Citations (PDF) |
| 184 | Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia | 3.6 | 139 | Citations (PDF) |
| 185 | Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease | 21.2 | 156 | Citations (PDF) |
| 186 | Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness | 10.6 | 41 | Citations (PDF) |
| 187 | Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct‐acting antiviral therapy | 2.7 | 14 | Citations (PDF) |
| 188 | Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis | 6.2 | 79 | Citations (PDF) |
| 189 | Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma | 3.9 | 22 | Citations (PDF) |
| 190 | Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis | 23.6 | 888 | Citations (PDF) |
| 191 | Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study | 5.4 | 27 | Citations (PDF) |
| 192 | Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease | 6.2 | 156 | Citations (PDF) |
| 193 | Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective | 2.5 | 16 | Citations (PDF) |
| 194 | Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding | 3.9 | 51 | Citations (PDF) |
| 195 | Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life | 0.7 | 48 | Citations (PDF) |
| 196 | Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease | 0.7 | 87 | Citations (PDF) |
| 197 | Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B | 4.1 | 32 | Citations (PDF) |
| 198 | Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis | 10.6 | 1,628 | Citations (PDF) |
| 199 | Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone | 4.1 | 9 | Citations (PDF) |
| 200 | HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues | 3.6 | 269 | Citations (PDF) |
| 201 | Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis | 2.6 | 31 | Citations (PDF) |
| 202 | Can the same controlled attenuation parameter cut‐offs be used for M and XL probes for diagnosing hepatic steatosis? | 2.7 | 48 | Citations (PDF) |
| 203 | Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement | 3.9 | 50 | Citations (PDF) |
| 204 | Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region—the <scp>GO ASIA</scp> initiative | 3.9 | 65 | Citations (PDF) |
| 205 | Review article: long‐term safety of oral anti‐viral treatment for chronic hepatitis B | 3.9 | 73 | Citations (PDF) |
| 206 | Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen | 6.2 | 58 | Citations (PDF) |
| 207 | Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016 | 5.4 | 45 | Citations (PDF) |
| 208 | Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B | 3.6 | 159 | Citations (PDF) |
| 209 | Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment | 2.7 | 430 | Citations (PDF) |
| 210 | The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups | 2.7 | 152 | Citations (PDF) |
| 211 | Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territory‐wide cohort study | 2.7 | 11 | Citations (PDF) |
| 212 | Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients | 3.6 | 98 | Citations (PDF) |
| 213 | Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes | 3.6 | 77 | Citations (PDF) |
| 214 | Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta‐analysis of a complex issue | 4.1 | 81 | Citations (PDF) |
| 215 | A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis | 10.6 | 599 | Citations (PDF) |
| 216 | Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients | 2.4 | 26 | Citations (PDF) |
| 217 | An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma | 13.9 | 83 | Citations (PDF) |
| 218 | Letter: chronic kidney disease risk in patients with chronic hepatitis B—authors’ reply | 3.9 | 0 | Citations (PDF) |
| 219 | On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis | 0.7 | 25 | Citations (PDF) |
| 220 | Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B | 3.6 | 96 | Citations (PDF) |
| 221 | Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations | 2.1 | 494 | Citations (PDF) |
| 222 | Noninvasive biomarkers in NAFLD and NASH — current progress and future promise | 48.0 | 540 | Citations (PDF) |
| 223 | Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis | 3.6 | 131 | Citations (PDF) |
| 224 | Systematic review with meta-analysis: Change in liver stiffness during anti-viral therapy in patients with hepatitis B | 2.4 | 29 | Citations (PDF) |
| 225 | Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study | 1.0 | 718 | Citations (PDF) |
| 226 | Territory‐wide population‐based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong | 4.1 | 17 | Citations (PDF) |
| 227 | Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease | 3.6 | 280 | Citations (PDF) |
| 228 | Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment | 3.9 | 67 | Citations (PDF) |
| 229 | Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer | 21.2 | 1,130 | Citations (PDF) |
| 230 | Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non‐alcoholic fatty liver disease in an Asian population | 5.0 | 78 | Citations (PDF) |
| 231 | Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients | 10.6 | 312 | Citations (PDF) |
| 232 | Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis | 10.6 | 1,674 | Citations (PDF) |
| 233 | Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis | 6.2 | 50 | Citations (PDF) |
| 234 | Long‐term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk – a cohort study of 44 494 subjects | 3.9 | 25 | Citations (PDF) |
| 235 | Mechanism and prediction of HCC development in HBV infection | 3.0 | 28 | Citations (PDF) |
| 236 | Significant positive association of endotoxemia with histological severity in 237 patients with non‐alcoholic fatty liver disease | 3.9 | 74 | Citations (PDF) |
| 237 | HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis | 0.7 | 46 | Citations (PDF) |
| 238 | Cost‐effectiveness of the highly effective direct‐acting antivirals in the treatment of chronic hepatitis C in Hong Kong | 2.7 | 7 | Citations (PDF) |
| 239 | Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter | 3.6 | 136 | Citations (PDF) |
| 240 | New trends on obesity and NAFLD in Asia | 3.6 | 976 | Citations (PDF) |
| 241 | Laboratory parameter‐based machine learning model for excluding non‐alcoholic fatty liver disease (<scp>NAFLD</scp>) in the general population | 3.9 | 172 | Citations (PDF) |
| 242 | Non-alcoholic fatty liver disease – demographic features, risk factors and treatment practices across the Asia Pacific region – the GO ASIA initiative | 3.6 | 0 | Citations (PDF) |
| 243 | Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis | 3.6 | 1,071 | Citations (PDF) |
| 244 | Application of the combined FibroMeter vibration‐controlled transient elastography algorithm in Chinese patients with non‐alcoholic fatty liver disease | 2.7 | 54 | Citations (PDF) |
| 245 | Prognostic Value of Controlled Attenuation Parameter by Transient Elastography | 0.7 | 78 | Citations (PDF) |
| 246 | Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis | 3.9 | 58 | Citations (PDF) |
| 247 | Serial combination of non‐invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with <scp>NAFLD</scp> | 3.9 | 156 | Citations (PDF) |
| 248 | Managing HCC in NAFLD | 0.7 | 3 | Citations (PDF) |
| 249 | Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance | 3.6 | 138 | Citations (PDF) |
| 250 | The role of quantitative hepatitis B surface antigen revisited | 3.6 | 317 | Citations (PDF) |
| 251 | Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong | 2.7 | 16 | Citations (PDF) |
| 252 | Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values | 10.6 | 203 | Citations (PDF) |
| 253 | Liver stiffness measurement predicts high‐grade post‐hepatectomy liver failure: A prospective cohort study | 2.7 | 43 | Citations (PDF) |
| 254 | Utility and Safety of Tolvaptan in Cirrhotic Patients with Hyponatremia: a Prospective Cohort Study | 1.6 | 13 | Citations (PDF) |
| 255 | Invasive and non-invasive assessment of portal hypertension | 4.5 | 55 | Citations (PDF) |
| 256 | Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non‐selective beta‐blockers | 1.8 | 32 | Citations (PDF) |
| 257 | Controlled attenuation parameter for the diagnosis of steatosis in non‐alcoholic fatty liver disease | 2.7 | 168 | Citations (PDF) |
| 258 | Long‐term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study | 10.6 | 127 | Citations (PDF) |
| 259 | Virus and Host Testing to Manage Chronic Hepatitis B | 5.4 | 14 | Citations (PDF) |
| 260 | Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B | 10.6 | 27 | Citations (PDF) |
| 261 | Pathogenesis and novel treatment options for non-alcoholic steatohepatitis | 23.6 | 171 | Citations (PDF) |
| 262 | In search of new biomarkers for nonalcoholic fatty liver disease | 1.4 | 10 | Citations (PDF) |
| 263 | Critical Role of Antimicrobial Peptide Cathelicidin for Controlling <i>Helicobacter pylori</i> Survival and Infection | 0.6 | 56 | Citations (PDF) |
| 264 | Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study | 21.2 | 439 | Citations (PDF) |
| 265 | Nonalcoholic fatty liver disease | 50.7 | 760 | Citations (PDF) |
| 266 | Long‐term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects | 10.6 | 88 | Citations (PDF) |
| 267 | Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? | 3.6 | 110 | Citations (PDF) |
| 268 | Adverse Effects of Vitamin D Deficiency on Outcomes of Patients With Chronic Hepatitis B | 6.2 | 58 | Citations (PDF) |
| 269 | Impact of <i><scp>IL28B</scp></i> and <i><scp>PNPLA3</scp></i> polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis <scp>C</scp> virus | 2.7 | 7 | Citations (PDF) |
| 270 | Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients | 7.6 | 653 | Citations (PDF) |
| 271 | <i><scp>PNPLA</scp>3</i> gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease | 2.7 | 147 | Citations (PDF) |
| 272 | Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients | 2.3 | 19 | Citations (PDF) |
| 273 | Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study | 21.2 | 204 | Citations (PDF) |
| 274 | Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy | 0.7 | 276 | Citations (PDF) |
| 275 | Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis | 3.6 | 94 | Citations (PDF) |
| 276 | Huge Adrenal Hemangioma: A Rare Cause of Deceivingly High Liver Stiffness Measurement by Transient Elastography | 6.2 | 7 | Citations (PDF) |
| 277 | Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy | 3.6 | 157 | Citations (PDF) |
| 278 | Histone Deacetylase 8 Is a Novel Chromatin Modulator in NAFLD-Associated Hepatocarcinogenesis | 6.2 | 2 | Citations (PDF) |
| 279 | Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B | 6.2 | 12 | Citations (PDF) |
| 280 | Noninvasive assessments of liver fibrosis with transient elastography and <scp>H</scp>ui index predict survival in patients with chronic hepatitis <scp>B</scp> | 2.7 | 13 | Citations (PDF) |
| 281 | Higher Estimated Net Endogenous Acid Production May Be Associated with Increased Prevalence of Nonalcoholic Fatty Liver Disease in Chinese Adults in Hong Kong | 2.4 | 33 | Citations (PDF) |
| 282 | Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy | 2.4 | 95 | Citations (PDF) |
| 283 | One‐stop clinic for ketamine‐associated uropathy: report on service delivery model, patients' characteristics and non‐invasive investigations at baseline by a cross‐sectional study in a prospective cohort of 318 teenagers and young adults | 3.3 | 48 | Citations (PDF) |
| 284 | Targeted hepatitis <scp>C</scp> screening among ex‐injection drug users in the community | 2.7 | 29 | Citations (PDF) |
| 285 | Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese | 3.6 | 73 | Citations (PDF) |
| 286 | Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B | 3.6 | 259 | Citations (PDF) |
| 287 | Fatty Pancreas, Insulin Resistance, and β-Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging | 0.7 | 245 | Citations (PDF) |
| 288 | Liver Injury Is Common Among Chronic Abusers of Ketamine | 6.2 | 68 | Citations (PDF) |
| 289 | Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease | 14.1 | 95 | Citations (PDF) |
| 290 | Association Between Anthropometric Parameters and Measurements of Liver Stiffness by Transient Elastography | 6.2 | 73 | Citations (PDF) |
| 291 | Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis <scp>B</scp>: A prospective cohort study with paired transient elastography examination | 2.7 | 40 | Citations (PDF) |
| 292 | Treatment of non‐alcoholic steatohepatitis with <i><scp>P</scp>hyllanthus urinaria</i>: A randomized trial | 2.7 | 27 | Citations (PDF) |
| 293 | Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis | 10.6 | 450 | Citations (PDF) |
| 294 | Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment | 1.0 | 161 | Citations (PDF) |
| 295 | Nonalcoholic fatty liver disease in <scp>A</scp>sia: A story of growth | 2.7 | 65 | Citations (PDF) |
| 296 | Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial | 3.6 | 306 | Citations (PDF) |
| 297 | NAFLD in Asia—as common and important as in the West | 48.0 | 415 | Citations (PDF) |
| 298 | Quantitative Elastography of Liver Fibrosis and Spleen Stiffness in Chronic Hepatitis B Carriers: Comparison of Shear-Wave Elastography and Transient Elastography with Liver Biopsy Correlation | 8.9 | 291 | Citations (PDF) |
| 299 | Liver fibrosis progression in chronic hepatitis <scp>B</scp> patients positive for hepatitis <scp>B</scp> e antigen: A prospective cohort study with paired transient elastography examination | 2.7 | 24 | Citations (PDF) |
| 300 | Chronic Hepatitis B: A Treatment Update | 3.4 | 14 | Citations (PDF) |
| 301 | Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes | 4.7 | 106 | Citations (PDF) |
| 302 | Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy | 4.8 | 42 | Citations (PDF) |
| 303 | Efficacy of Entecavir Switch Therapy in Chronic Hepatitis B Patients with Incomplete Virological Response to Telbivudine | 2.1 | 8 | Citations (PDF) |
| 304 | Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis – A Longitudinal Study | 2.4 | 295 | Citations (PDF) |
| 305 | Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study | 1.6 | 296 | Citations (PDF) |
| 306 | Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography | 21.2 | 466 | Citations (PDF) |
| 307 | Diagnosis and personalized management of hepatitis B including significance of genotypes | 3.5 | 15 | Citations (PDF) |
| 308 | Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease | 0.7 | 316 | Citations (PDF) |
| 309 | Hepatitis B virus infection and fatty liver in the general population | 3.6 | 217 | Citations (PDF) |
| 310 | Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan® | 3.6 | 230 | Citations (PDF) |
| 311 | Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers | 3.6 | 223 | Citations (PDF) |
| 312 | Endoscopic Pancreatic Necrosectomy: Notes of Excitement | 1.0 | 0 | Citations (PDF) |
| 313 | A randomized comparison of ultrathin and standard colonoscope in cecal intubation rate and patient tolerance | 1.9 | 22 | Citations (PDF) |
| 314 | 606: Maternal HBeAg status and hepatitis B viral activity in HBsAg positive mothers | 2.4 | 0 | Citations (PDF) |
| 315 | High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis | 21.2 | 237 | Citations (PDF) |
| 316 | Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B | 3.6 | 125 | Citations (PDF) |
| 317 | Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease? | 3.6 | 6 | Citations (PDF) |
| 318 | Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score | 26.0 | 620 | Citations (PDF) |
| 319 | On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients | 2.1 | 92 | Citations (PDF) |
| 320 | Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground | 2.7 | 138 | Citations (PDF) |
| 321 | Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test? | 2.7 | 4 | Citations (PDF) |
| 322 | The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography | 4.1 | 37 | Citations (PDF) |
| 323 | Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease | 21.2 | 272 | Citations (PDF) |
| 324 | Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients | 3.8 | 118 | Citations (PDF) |
| 325 | Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B | 2.3 | 7 | Citations (PDF) |
| 326 | Carboxyl-Terminal Truncated HBx Regulates a Distinct MicroRNA Transcription Program in Hepatocellular Carcinoma Development | 2.4 | 77 | Citations (PDF) |
| 327 | Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy | 2.1 | 38 | Citations (PDF) |
| 328 | Continuation of Low-Dose Aspirin Therapy in Peptic Ulcer Bleeding | 10.4 | 417 | Citations (PDF) |
| 329 | Impact of Antiviral Therapy on Risk of Hepatocellular Carcinoma | 1.0 | 0 | Citations (PDF) |
| 330 | Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital | 2.3 | 19 | Citations (PDF) |
| 331 | Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease | 10.6 | 1,174 | Citations (PDF) |
| 332 | Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B | 10.6 | 105 | Citations (PDF) |
| 333 | A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B | 10.6 | 235 | Citations (PDF) |
| 334 | Transient elastography | 2.7 | 85 | Citations (PDF) |
| 335 | Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years | 21.2 | 580 | Citations (PDF) |
| 336 | Hepatitis B Virus (HBV) Subgenotypes C2 and B2 Differ in Lamivudine- and Adefovir-Resistance-Associated Mutational Patterns in HBV-Infected Chinese Patients | 4.1 | 37 | Citations (PDF) |
| 337 | Interaction of Adipokines and Hepatitis B Virus on Histological Liver Injury in the Chinese | 0.7 | 65 | Citations (PDF) |
| 338 | Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy | 3.1 | 17 | Citations (PDF) |
| 339 | 723 A SIMPLE BREATH TEST CAN ASSESS LIVER FUNCTION AND PREDICT CLINICAL OUTCOME IN CHRONIC HEPATITIS B | 3.6 | 0 | Citations (PDF) |
| 340 | Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure | 4.5 | 66 | Citations (PDF) |
| 341 | Bacterial Microbiota Profiling in Gastritis without Helicobacter pylori Infection or Non-Steroidal Anti-Inflammatory Drug Use | 2.4 | 222 | Citations (PDF) |
| 342 | Long-term Follow-up of Ulcerative Colitis in the Chinese Population | 0.7 | 93 | Citations (PDF) |
| 343 | Evaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma | 4.1 | 23 | Citations (PDF) |
| 344 | Antiviral therapy for chronic hepatitis B: are we doing any good to patients? | 3.2 | 2 | Citations (PDF) |
| 345 | High serum interleukin‐6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B | 4.5 | 203 | Citations (PDF) |
| 346 | Cyclooxygenase-2 inhibitors in patients with high gastrointestinal risk: are we there yet? | 4.5 | 4 | Citations (PDF) |
| 347 | Interferon‐induced thyroid dysfunction—not always transient | 2.7 | 5 | Citations (PDF) |
| 348 | Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease | 2.7 | 69 | Citations (PDF) |
| 349 | Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B | 6.2 | 47 | Citations (PDF) |
| 350 | High Incidence of Mortality and Recurrent Bleeding in Patients With Helicobacter pylori–Negative Idiopathic Bleeding Ulcers | 1.0 | 134 | Citations (PDF) |
| 351 | Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen–Positive Chronic Hepatitis B Patients | 6.2 | 77 | Citations (PDF) |
| 352 | 921 IS THE ROADMAP MODEL COST-EFFECTIVE IN THE ERA OF TENOFOVIR IN THE TREATMENT OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION? | 3.6 | 0 | Citations (PDF) |
| 353 | Predicting Mortality in Patients With Bleeding Peptic Ulcers After Therapeutic Endoscopy | 6.2 | 93 | Citations (PDF) |
| 354 | Hepatitis B Virus Genotype C Is Associated With More Severe Liver Fibrosis Than Genotype B | 6.2 | 77 | Citations (PDF) |
| 355 | A review of the natural history of chronic hepatitis B in the era of transient elastography | 2.1 | 35 | Citations (PDF) |
| 356 | Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis | 4.1 | 109 | Citations (PDF) |
| 357 | Genetic polymorphisms of adiponectin and tumor necrosis factor‐alpha and nonalcoholic fatty liver disease in Chinese people | 2.7 | 61 | Citations (PDF) |
| 358 | Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment | 6.2 | 25 | Citations (PDF) |
| 359 | Assessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases | 6.2 | 147 | Citations (PDF) |
| 360 | Validation of the NAFLD Fibrosis Score in a Chinese Population With Low Prevalence of Advanced Fibrosis | 0.7 | 105 | Citations (PDF) |
| 361 | Evaluation of Alanine Transaminase and Hepatitis B Virus DNA to Predict Liver Cirrhosis in Hepatitis B e Antigen-Negative Chronic Hepatitis B Using Transient Elastography | 0.7 | 85 | Citations (PDF) |
| 362 | High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma | 21.6 | 288 | Citations (PDF) |
| 363 | Hepatocyte growth factor promotes proliferation and migration in immortalized progenitor cells | 1.5 | 19 | Citations (PDF) |
| 364 | Long-Term follow-up of Lamivudine Treatment in Patients with Severe Acute Exacerbation of Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B | 2.1 | 33 | Citations (PDF) |
| 365 | Virodynamic Predictors of Response to Pegylated Interferon and Lamivudine Combination Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B | 2.1 | 3 | Citations (PDF) |
| 366 | Initial Treatment With Lansoprazole in Young Dyspeptic Patients With Negative Urea Breath Test Result: A Randomized Controlled Trial With 12-Month Follow-Up | 0.7 | 11 | Citations (PDF) |
| 367 | Small bowel enteropathy associated with chronic low-dose aspirin therapy | 52.8 | 48 | Citations (PDF) |
| 368 | Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response | 6.2 | 331 | Citations (PDF) |
| 369 | Distinct Clinical Characteristics Between Patients With Nonerosive Reflux Disease and Those With Reflux Esophagitis | 6.2 | 102 | Citations (PDF) |
| 370 | Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in chinese patients with chronic hepatitis B | 2.6 | 56 | Citations (PDF) |
| 371 | Virological Response to Different Combination Regimes of Peginterferon α-2b and Lamivudine in Hepatitis B e Antigen Positive Chronic Hepatitis B | 2.1 | 29 | Citations (PDF) |
| 372 | Metabolic and Adipokine Profile of Chinese Patients With Nonalcoholic Fatty Liver Disease | 6.2 | 186 | Citations (PDF) |
| 373 | Expression profilings of 39 genes selected by ANOVA could separate precursors of murine dendritic cells and macrophages | 2.1 | 0 | Citations (PDF) |
| 374 | Evaluation of Model for End-Stage Liver Disease for Prediction of Mortality in Decompensated Chronic Hepatitis B | 0.7 | 59 | Citations (PDF) |
| 375 | Long-Term Lamivudine Treatment is Associated with a Good Maintained Response in Severe Acute Exacerbation of Chronic Hbeag-Negative Hepatitis B | 2.1 | 28 | Citations (PDF) |
| 376 | Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B | 10.6 | 77 | Citations (PDF) |
| 377 | A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-α2b and Lamivudine with Lamivudine Alone | 10.4 | 248 | Citations (PDF) |
| 378 | Identification of Chronic Hepatitis B Patients without Significant Liver Fibrosis by a Simple Noninvasive Predictive Model | 0.7 | 207 | Citations (PDF) |
| 379 | A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients | 3.2 | 29 | Citations (PDF) |
| 380 | A Retrospective Study on Clinical Features and Prognostic Factors of Biopsy-Proven Primary Biliary Cirrhosis in Chinese Patients | 0.7 | 30 | Citations (PDF) |
| 381 | Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: Results of a randomized double-blind trial | 1.0 | 146 | Citations (PDF) |
| 382 | Upper gastrointestinal complications related to non-steroidal anti-inflammatory drugs—what have we achieved so far? | 2.4 | 4 | Citations (PDF) |
| 383 | A cirrhotic patient with fever and abdominal pain in the presence of ascites | 0.2 | 1 | Citations (PDF) |
| 384 | Hepatocellular carcinoma surveillance after HBsAg seroclearance 0, , 175-189 | | 0 | Citations (PDF) |
